The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.
“The clinical profile and tolerability of oral [selinexor] provides physicians and patients with a new treatment alternative to traditional intravenous chemotherapy regimens,” noted John